NVAX as reported
Novavax, Inc. reported $596M of revenue over the trailing twelve months, −52% on the year before. 10 reported series are charted on this page, each one as filed.
$596M
Revenue, trailing twelve months · to Q1 2026 · −52% against the twelve months before
- Net Income
- −$88M
Net Income · −118% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$97M
Free Cash Flow · −51% year on year · trailing twelve months to Q1 2026
- Op Margin
- −53%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $596M | −52% | Q1 2026 |
| Net Income | −$88M | −118% | Q1 2026 |
| EPS | −$0.64 | −124% | Q1 2026 |
| Gross Margin | 82% | n/a | Q1 2026 |
| Op Margin | −53% | n/a | Q1 2026 |
| Net Margin | −59% | n/a | Q1 2026 |
| ROE | 155% | n/a | Q1 2026 |
| ROA | 22% | n/a | Q1 2026 |
| ROIC | 82% | n/a | Q4 2016 · 37 quarters behind |
| Free Cash Flow | −$97M | −51% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Novavax, Inc. (NVAX) - Revenue & ProfitRevenue & ProfitNovavax, Inc. (NVAX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com